AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

FDA

There’s a New Humira Challenger as Coherus Biosimilar Wins Approval

Shares of Coherus BioSciences are climbing in premarket trading after the company announced the FDA greenlit the company’s Humira biosimilar Yusimry.

December 20, 2021

2 min read

Alex Keown

Drug Development

Notch Another Win for AbbVie’s Rinvoq, This Time in Psoriatic Arthritis

The FDA approved the latest indication for Rinvoq (upadacitinib) based on data from two Phase III studies, SELECT-PsA 1 and SELECT-PsA 2.

December 15, 2021

2 min read

Alex Keown

Policy

Texas Goes After Pharmas for Alleged Use of Hormone Drugs to Treat Gender Dysphoria

Texas’ top law enforcement official is taking aim at two drug companies over what he alleges is the promotion of hormone blockers for children experiencing gender dysphoria.

December 14, 2021

2 min read

Alex Keown

Business

Former Scripps and Humira Leader Richard Lerner Passes Away

Richard Lerner, who played a significant role in shaping both Scripps Research and the San Diego life sciences ecosystem and developing AbbVie’s blockbuster drug Humira, died Dec. 2.

December 7, 2021

3 min read

Alex Keown

FDA

New FDA Safety Warning Potentially Bad News for JAK Market

The regulatory agency just placed new safety warnings on that drug class, which will impact AbbVie’s Rinvoq (upadacitinib), a drug the company has seen as a successor to its revenue-driving Humira.

December 6, 2021

3 min read

Alex Keown

Business

Warren Buffet Scales Back Big Biopharma Investments

This week, Berkshire announced that it has scaled back those investments, and completely eliminated its stake in Merck.

November 17, 2021

2 min read

Heather McKenzie

BioCapital

Clinical Catch-Up: November 8-12

It was another busy week for clinical trial news. Here’s a look.

November 12, 2021

12 min read

Mark Terry

Policy

Oklahoma’s Highest Court Overturns Landmark Opioid Verdict Against J&J

The Oklahoma Supreme Court has overturned the landmark $465 million opioid verdict handed down against Johnson & Johnson in 2019.

November 9, 2021

2 min read

Heather McKenzie

Drug Development

FDA Approval of AbbVie Eye Drop a New Moment in Presbyopia Treatment

The decision made VUITY the very first and only eye drop to be approved for the Presbyopia treatment. Follow the article to know aspects of this new treatment.

November 1, 2021

2 min read

Kaylei Whalen

JOBS